PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
September 28, 2023Current Opinion in PhysiologyOpen Access

Potential of β2AR for added benefit in treating heart failure through a better understanding of signaling

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Key result

Understanding the broader signaling repertoire of the β2-adrenoceptor, including allosteric binding and pepducins, offers potential for cardioprotection and new therapeutics in heart failure.

Authors

KWKafa WalweelECElizabeth CheesmanPMPeter Molenaar

Discussion

Loading...

Member takes

Overview

Hypothesis-generating for biased β2AR ligands in HF; prospective trials needed before any practice change.

Structured PICO

P
Population
Human heart, cell, and animal models of heart failure
I
Intervention
Modulation of β2-adrenoceptor (β2AR) signaling (including orthosteric, allosteric binding, and pepducins)
O
Outcome
Contractile force, arrhythmogenesis, and cardioprotection

A broader understanding of β2AR signaling, including allosteric modulation and β-arrestin pathways, may offer novel therapeutic strategies for heart failure.

Limitations

  • Beneficial effects are still waiting for translation to the human diseased heart

Cite This Study

Walweel et al. (2023) conducted a review in Heart failure. β2-adrenoceptor (β2AR) targeted therapeutics was evaluated. Understanding the broader signaling repertoire of the β2-adrenoceptor, including allosteric binding and pepducins, offers potential for cardioprotection and new therapeutics in heart failure.

synapsesocial.com/papers/6a08caec96b78901e666c1e7https://doi.org/10.1016/j.cophys.2023.100719
View Full Paper
Ask AI
Bookmark
Share